Remove 2027 Remove Compounding Remove FDA
article thumbnail

Social Media Significantly Influences Attitudes, Behaviors Toward Skin Health

Drug Topics

billion people used social media in 2021, and this number is likely to grow to almost 6 billion in 2027. FDA Approves Roflumilast Foam For Plaque Psoriasis of Scalp, Body Ashley Gallagher May 22nd 2025 Article The supplemental new drug application for roflumilast (Zoryve) is approved for adult and pediatric patients 12 years and older.

article thumbnail

STAT+: Pharmalittle: We’re reading about FDA eyeing PDUFA changes, compounded weight loss drugs, and more

STAT

… Online weight loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk’s Wegovy as the U.S. Noom offers its compounded semaglutide at a starting price of $149 for the first month. The current legislative authority for the programs expires at the end of September 2027.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: ‘Learning each other’s language’: FDA, patent office seek to work together to lower drug prices

STAT

Not long after the patent was awarded, the company leveraged federally funded research and began investigating different forms of the compound, called Revlimid. One expires next year and the other in 2027, well beyond the original patent expiration date.

FDA 123
article thumbnail

ViiV claims $1.25bn settlement from Gilead in HIV patent dispute

pharmaphorum

ViiV claimed the latter compound infringes its patents for dolutegravir and other compounds based on the drug’s chemical scaffold. The dispute centred around Gilead’s triple-drug regimen Biktarvy , which is based on emtricitabine, tenofovir alafenamide and integrase inhibitor bictegravir.

article thumbnail

Top Performing Drug of 2021 - Trulicity (February Edition)

PharmaShots

Some of its FDA-approved competitors include: Patents7 Eli Lilly carries big expectations from Trulicity to boost its revenue. In the US, Trulicity is protected by a compound patent (2027) and by biologics data protection (2026).

article thumbnail

FDA Approves Immunoglobulin Formulation With Low IgA Content for Primary Immunodeficiency

Pharmacy Times

Takeda will discontinue Gammagard S/D by December 2027, transitioning to the new low IgA formulation. The new formulation is contraindicated in patients with severe hypersensitivity to immunoglobulin products, requiring careful monitoring.

FDA 97
article thumbnail

T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies

Pharmaceutical Technology

billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. However, Invokana is likely to continue to lose market share (forecast 9MM CAGR decline of 14.6%), due to an FDA boxed warning regarding diabetic ketoacidosis and increased risk of lower limb amputations.